New drug combo aims to shrink tough lung cancers

NCT ID NCT07405190

Recruiting now Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 16, 2026 · Updated 3 times

Summary

This Phase 2 trial tests a drug called ivonescimab, either alone or with chemotherapy, in people with advanced non-small cell lung cancer that has certain genetic changes. The study aims to see if the treatment can shrink tumors and control the cancer. About 46 participants will receive infusions every 3 weeks for up to 24 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ivonescimab (a drug that targets PD-1 and VEGF-A), carboplatin, and pemetrexed
What this could lead to: If successful, this could offer a new treatment option for people with advanced lung cancer that has specific genetic changes and has stopped responding to other therapies.
What could go wrong: This is an early Phase 2 trial with only 46 participants, so results may not apply to everyone. The drug may not shrink tumors or could cause side effects like immune-related reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER WITH NTRK1-3 FUSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

disease of genetic or genomic mechanism lung cancer lung neoplasm non-small cell lung carcinoma NTRK fusion positive cancer RET fusion positive cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENOMIC ALTERATIONS LUNG CANCER (NON-SMALL CELL) LUNG CANCER (NSCLC) LUNG CANCER NON-SMALL CELL CANCER (NSCLC)

Contacts and locations

Locations

Beth Israel Deaconess Medical Center
NOT_YET_RECRUITING

Boston, Massachusetts, 02215, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.